BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33789824)

  • 1. Tumor control and cosmetic outcome of weekly iridium-192 high-dose-rate brachytherapy for nonmelanoma skin cancers in the elderly.
    Roberson J; Patel R; Slutsky JB; Ryu S; Xu Z; Valentine E
    Brachytherapy; 2021; 20(4):818-827. PubMed ID: 33789824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer.
    Paravati AJ; Hawkins PG; Martin AN; Mansy G; Rahn DA; Advani SJ; Hoisak J; Dragojevic I; Martin PJ; Miller CJ; Sanghvi P
    Pract Radiat Oncol; 2015; 5(6):e659-64. PubMed ID: 26432680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Custom mold applicator high-dose-rate brachytherapy for nonmelanoma skin cancer-An analysis of 273 lesions.
    Olek D; El-Ghamry MN; Deb N; Thawani N; Shaver C; Mutyala S
    Brachytherapy; 2018; 17(3):601-608. PubMed ID: 29398593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
    Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment.
    Arenas M; Arguís M; Díez-Presa L; Henríquez I; Murcia-Mejía M; Gascón M; Gómez D; Lafuerza A; Mur E; Azón A; Rovirosa À; Sabater S
    Brachytherapy; 2015; 14(6):859-65. PubMed ID: 26489922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDR brachytherapy for superficial non-melanoma skin cancers.
    Gauden R; Pracy M; Avery AM; Hodgetts I; Gauden S
    J Med Imaging Radiat Oncol; 2013 Apr; 57(2):212-7. PubMed ID: 23551783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response of endemic Kaposi sarcoma lesions with high-dose-rate brachytherapy: treatment method, results, and toxicity using skin surface applicators.
    Kasper ME; Richter S; Warren N; Benda R; Shang C; Ouhib Z
    Brachytherapy; 2013; 12(5):495-9. PubMed ID: 23466358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
    Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
    Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year.
    Bhatnagar A
    Brachytherapy; 2013; 12(2):134-40. PubMed ID: 23312675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 Trial of Accelerated Partial Breast Irradiation (APBI) Using Noninvasive Image Guided Breast Brachytherapy (NIBB).
    Hepel JT; Leonard KL; Sha S; Graves TA; Wiggins DL; Mastras D; Pittier A; ; Wazer DE
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1143-1149. PubMed ID: 32721422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended (5-year) outcomes of accelerated partial breast irradiation using MammoSite balloon brachytherapy: patterns of failure, patient selection, and dosimetric correlates for late toxicity.
    Vargo JA; Verma V; Kim H; Kalash R; Heron DE; Johnson R; Beriwal S
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):285-91. PubMed ID: 24268787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate brachytherapy for facial skin cancer: Outcome and toxicity assessment for 71 cases.
    Renard S; Salleron J; Py JF; Cuenin M; Buchheit I; Marchesi V; Huger S; Meknaci E; Peiffert D
    Brachytherapy; 2021; 20(3):624-630. PubMed ID: 33685816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
    Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer.
    Mattiucci GC; Autorino R; Tringali A; Perri V; Balducci M; Deodato F; Gambacorta MA; Mantini G; Tagliaferri L; Mutignani M; Morganti AG
    Brachytherapy; 2015; 14(3):401-4. PubMed ID: 25591935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.
    Chin YS; Bullard J; Bryant L; Bownes P; Ostler P; Hoskin PJ
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):474-9. PubMed ID: 16909971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose-rate brachytherapy in uterine cervical carcinoma.
    Patel FD; Rai B; Mallick I; Sharma SC
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):125-30. PubMed ID: 15850912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy.
    Strom TJ; Wilder RB; Fernandez DC; Mellon EA; Saini AS; Hunt DC; Biagioli MC
    Brachytherapy; 2014; 13(2):123-7. PubMed ID: 24269146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.